First REIT Divests Indonesian Assets for S$471.5mn, Target Price Reduced to S$0.25 with ACCUMULATE Rating April 24, 2026

First REIT Divests Indonesian Assets for S$471.5mn, Target Price Reduced to S$0.25 with ACCUMULATE Rating

Strategic Divestment to Enhance Portfolio Quality

First REIT has announced a comprehensive divestment strategy for its Indonesian healthcare assets, proposing to sell eight hospitals and three non-hospital properties for S$471.5mn. The purchaser, PT Siloam International Hospitals Tbk, will acquire these assets in the first tranche of what represents a strategic pivot towards developed markets.


Company Overview

First REIT operates as a healthcare-focused real estate investment trust with assets spanning Singapore, Japan, and Indonesia. The REIT specialises in healthcare properties including hospitals and medical facilities across the Asia-Pacific region.


Two-Tranche Divestment Structure

The proposed transaction follows a carefully structured two-phase approach. The initial tranche involves eleven Indonesian assets valued at S$471.5mn, comprising eight hospitals for IDR5.1tn (S$389.2mn) and three non-hospital assets for IDR1.1tn (S$82.4mn). This pricing represents a 2.1% premium over the average of two recent independent valuations.

Additionally, First REIT has secured a put option for the remaining six Indonesian hospitals, valued at S$294.8mn, exercisable until 31 October 2026. This structure provides flexibility whilst ensuring complete exit from the Indonesian market if desired.


Financial Impact and Capital Allocation

The divestment will generate significant financial benefits for unitholders. The S$9.7mn premium over appraised value will be distributed as special dividends over two quarters following completion. The manager has waived its S$2.4mn divestment fee to align with unitholder interests.

Net proceeds of S$464.2mn will primarily reduce debt, with S$362.7mn (78%) allocated to debt repayment. This will dramatically improve the REIT’s leverage profile, reducing aggregate leverage from 42.1% to 16.7%. The remaining debt will largely comprise lower-cost JPY-denominated borrowings.


Strategic Outlook and Research Recommendation

The divestment addresses rental arrears issues whilst enabling capital recycling from non-core assets. First REIT plans to focus on assets in Singapore and Japan whilst pursuing expansion opportunities in developed markets, which offer lower equity risk premiums, reduced debt costs, and more stable currencies.

Phillip Securities Research maintains an ACCUMULATE recommendation with a revised target price of S$0.25, down from S$0.29. The valuation methodology has shifted to 1x FY25 P/NAV from the dividend discount model, reflecting uncertainty over future portfolio composition pending the strategic review.


Frequently Asked Questions

Q: What assets is First REIT proposing to divest?
A: First REIT is proposing to divest eight hospitals and three non-hospital assets in Indonesia for S$471.5mn, with an additional put option for six remaining hospitals at S$294.8mn.

Q: Who is purchasing the Indonesian assets?
A: PT Siloam International Hospitals Tbk (Siloam) is the purchaser of the eight hospitals in the first tranche.

Q: When will the divestment be completed?
A: The divestments are subject to unitholders’ approval at an Extraordinary General Meeting scheduled for June 2026, with targeted completion in August 2026.

Q: How will the proceeds be used?
A: Net proceeds of S$464.2mn will primarily reduce debt (S$362.7mn or 78%), with S$9.7mn distributed as special dividends and the remainder allocated to capital expenditure and working capital.

Q: What is Phillip Securities Research’s recommendation and target price?
A: Phillip Securities Research maintains ACCUMULATE with a lower target price of S$0.25, reduced from the previous S$0.29.

Q: How will the divestment impact leverage?
A: Aggregate leverage would decline significantly to 16.7% from the current 42.1%, assuming completion on 31 December 2025.

Q: What is First REIT’s strategic direction following the divestment?
A: First REIT plans to focus on Singapore and Japan assets whilst transitioning toward developed markets, which offer lower equity risk premiums, lower debt costs, and more stable currencies.

Q: Will unitholders receive any special distributions?
A: Yes, the S$9.7mn premium over appraised value will be distributed as special dividends over two quarters following completion of the divestment.


This article has been auto-generated using AI tools. It is based on a report by a Phillip Securities Research analyst.

 

Disclaimer

These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products.

Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance.

Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries.

The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries.

Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com